Home › Cytokinetics, Amgen drug shows promise in heart failure study
 

Keywords :   


Cytokinetics, Amgen drug shows promise in heart failure study

2015-11-09 05:29:58| Biotech - Topix.net

ORLANDO: An experimental heart failure drug being developed by Cytokinetics Inc and Amgen Inc demonstrated several beneficial cardiac function effects in a midstage clinical trial, according to data presented on Sunday. The trial of 448 patients with chronic heart failure already receiving optimal care tested a twice-a-day oral version of the drug, omecamtiv mecarbil, against a placebo over 20 weeks.

Tags: study shows heart drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Atlantic Tropical Weather Outlook
05.07Eastern North Pacific Tropical Weather Outlook
04.07Hurricane Beryl Graphics
04.07Hurricane Beryl Forecast Discussion Number 25
04.07Hurricane Beryl Public Advisory Number 25
04.07Summary for Hurricane Beryl (AT2/AL022024)
04.07Hurricane Beryl Wind Speed Probabilities Number 25
04.07Hurricane Beryl Forecast Advisory Number 25
More »